Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
Før og etter bilder

Scalp Hair Images

Eyebrow & Eyelash Images

Tab Number 3

Tab Number 4

Tab Number 5

See how LITFULO helped some patients achieve near-complete to complete (SALT ≤10) scalp hair regrowth1‐2
  • All patients from the study had 50% or more scalp hair loss at baseline
  • There was no statistical significance between LITFULO 50 mg and placebo at Week 12
  • In 6 months,
    •   13.4% of patients achieved SALT ≤10 with LITFULO 50 mg vs 1.5% with placebo
    •   23% of patients achieved SALT ≤20 with LITFULO 50 mg vs 1.6% with placebo
Patient images demonstrate an example of a patient who met the clinical trial primary endpoint of SALT ≤10 at Week 24. See clinical trial results. Individual results may vary.

Female, 22

 Male, 17

Female, 49

Female, 23

Tab Number 5

Patient images are used with permission.

 Explore safety data SikkerhetLoading
SALT=Severity of Alopecia Tool.
References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2023. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928.
See how LITFULO helped some patients achieve moderate-to-normal eyebrows and eyelashes1‐3
  • In 6 months, 29% of patients achieved moderate-to-normal eyebrows with LITFULO vs 4.7% with placebo
  • In 6 months, 28.9% of patients achieved moderate-to-normal eyelashes with LITFULO vs 5.2% with placebo
  • Response is based on at least a 2-grade improvement from baseline or a normal eyebrow or eyelash analysis score of 3*†‡

Age: 18
Sex: Male

Age: 29
Sex: Male

Inclusion in the study was not based on eyebrow or eyelash involvement. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 82% had abnormal eyebrows at baseline. Of the patients who received LITFULO 50 mg (n=130) or placebo (n=131), 73% and 74% had abnormal eyelashes at baseline respectively. Eyelash response was not adjusted for multiplicity at any point during the study.Eyebrow response and eyelash response (secondary endpoints for all study analyses) is based on at least a 2-grade improvement, or on a normal eyelash assessment (score of 3) on the Eyebrow Assessment Scale or Eyelash Assessment Scale among those with abnormal eyelashes at baseline.Patient images demonstrate an example of a patient who achieved moderate eyebrows or eyelashes at Week 24. Individual results may vary.

Patient images are used with permission.

 Explore safety data SikkerhetLoading
References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2. 3. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10;401(10392):1928.

tab 6

Explore safety data SikkerhetLoading
Get appropriate patients started on LITFULO today Kom i gangLoading
PP-LGF-NOR-0019 | Utarbeidet 08.2024

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei